Immunotherapy Continues to Excite in NSCLC – OncLive
|
Immunotherapy Continues to Excite in NSCLC
OncLive Feldman: I was asked to speak on first- and second-line immunotherapy in lung cancer, as well as third-line and beyond. I reviewed the various trials that led to the FDA approval of first-line therapy, such as pembrolizumab in patients who express more … |
